Advertisement

A Holistic Approach to Pain Management in the Rheumatic Diseases

  • Jon T. Golenbiewski
  • David S. PisetskyEmail author
Pain in Rheumatology (W Nielson, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pain in Rheumatology

Abstract

Purpose of the review

Pain is the most common symptom of patients with rheumatic disease, and its characteristics can be used to diagnose disease, assess disease activity, inform treatment decisions, and determine treatment response. Pain nevertheless remains one of the most difficult symptoms to evaluate and treat. Understanding the mechanisms of pain in the rheumatic diseases can provide a framework for a holistic approach to guide treatment decisions. In this article, we provide an overview on pain generation in rheumatologic disease, with a focus on rheumatoid arthritis, osteoarthritis, and fibromyalgia, and offer a perspective on treatment.

Recent findings

Pain in rheumatic disease can be divided into three categories: inflammation, damage, and pain processing and perception. The contribution of these mechanisms can change during the course of disease and characteristics of different causes of pain can be present at any given time. In view of the diverse mechanisms of pain in the individual patient, a personalized approach of pharmacologic and non-pharmacologic interventions can be used to address symptomatology.

Summary

The division of pain into the three categories of inflammation, damage, and pain processing and perception can provide a useful construct for pain assessment and management in patients with rheumatic disease. Given its complex nature, pain can be treated using a variety of pharmacologic and non-pharmacologic interventions. For patients with inflammatory arthritis, the underlying mechanism of pain should be frequently re-assessed and a holistic approach used to manage better this important symptom.

Keywords

Pain Rheumatoid arthritis Osteoarthritis Fibromyalgia Inflammation Sensitization 

Notes

Compliance with Ethical Standards

Conflict of Interest

Jon T. Golenbiewski declares that he has no conflict of interest. David S. Pisetsky declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Report of the American College of Rheumatology pain management task force. Arthritis Care Res. 2010;62(5):590–9.CrossRefGoogle Scholar
  2. 2.
    Malfait AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol. 2013;9(11):654–64.CrossRefGoogle Scholar
  3. 3.
    • Vardeh D, Mannion RJ, Woolf CJ. Toward a mechanism-based approach to pain diagnosis. J Pain. 2016;17(9 Suppl):T50–69. This article provides information of the underlying mechanisms of pain and the application to the development of treatment.CrossRefGoogle Scholar
  4. 4.
    Borenstein DG, Hassett AL, Pisetsky D. Pain management in rheumatology research, training, and practice. Clin Exp Rheumatol. 2017;35(Suppl 107(5)):2–7.Google Scholar
  5. 5.
    Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther. 2011;13(2):211.CrossRefGoogle Scholar
  6. 6.
    Woller SA, et al. An overview of pathways encoding nociception. Clin Exp Rheumatol. 2017;35(Suppl 107(5)):40–6.Google Scholar
  7. 7.
    • McWilliams DF, Walsh DA. Pain mechanisms in rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(Suppl 107(5)):94–101. A valuable review, this article addresses mechanisms of pain generation in rheumatoid arthritis.Google Scholar
  8. 8.
    Khanna D, et al. Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage. Arthritis Rheum. 2005;52(8):2284–92.CrossRefGoogle Scholar
  9. 9.
    Walsh DA, McWilliams DF. Mechanisms, impact and management of pain in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10(10):581–92.CrossRefGoogle Scholar
  10. 10.
    Boyden SD, et al. Non-inflammatory causes of pain in patients with rheumatoid arthritis. Curr Rheumatol Rep. 2016;18(6):30.CrossRefGoogle Scholar
  11. 11.
    Katz P. Causes and consequences of fatigue in rheumatoid arthritis. Curr Opin Rheumatol. 2017;29(3):269–76.CrossRefGoogle Scholar
  12. 12.
    Loeser RF, et al. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697–707.CrossRefGoogle Scholar
  13. 13.
    Dimitroulas T, et al. Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment. Semin Arthritis Rheum. 2014;44(2):145–54.CrossRefGoogle Scholar
  14. 14.
    Fu K, Robbins SR, McDougall JJ. Osteoarthritis: the genesis of pain. Rheumatology (Oxford). 2018;57(suppl_4):iv43–50.CrossRefGoogle Scholar
  15. 15.
    Choy EH. The role of sleep in pain and fibromyalgia. Nat Rev Rheumatol. 2015;11(9):513–20.CrossRefGoogle Scholar
  16. 16.
    •• Sluka KA, Clauw DJ. Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience. 2016;338:114–29. This article provides an in-depth review of the neurobiology of chronic pain and, in particular, explores the mechanisms of pain in fibromyalgia.CrossRefGoogle Scholar
  17. 17.
    Boomershine CS, Crofford LJ. A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol. 2009;5(4):191–9.CrossRefGoogle Scholar
  18. 18.
    Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol. 2007;26(4):465–73.CrossRefGoogle Scholar
  19. 19.
    Clauw DJ, Hassett AL. The role of centralised pain in osteoarthritis. Clin Exp Rheumatol. 2017;35(Suppl 107(5)):79–84.Google Scholar
  20. 20.
    Smolen JS. Treat-to-target as an approach in inflammatory arthritis. Curr Opin Rheumatol. 2016;28(3):297–302.CrossRefGoogle Scholar
  21. 21.
    Sokka T. Assessment of pain in rheumatic diseases. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S77–84.Google Scholar
  22. 22.
    Bailly F, Fautrel B, Gossec L. Pain assessment in rheumatology - how can we do better? A literature review. Joint Bone Spine. 2016;83(4):384–8.CrossRefGoogle Scholar
  23. 23.
    Chung F, Abdullah HR, Liao P. STOP-Bang Questionnaire: a practical approach to screen for obstructive sleep apnea. Chest. 2016;149(3):631–8.CrossRefGoogle Scholar
  24. 24.
    • Smithson S, Pignone MP. Screening adults for depression in primary care. Med Clin North Am. 2017;101(4):807–21. This article discusses mechanisms of pain in osteoarthritis in the context of management strategies.CrossRefGoogle Scholar
  25. 25.
    Hamilton NA, et al. Evaluating evidence for the role of sleep in fibromyalgia: a test of the Sleep and Pain Diathesis Model. Cognit Ther Res. 2012;36(6):806–14.CrossRefGoogle Scholar
  26. 26.
    Irwin MR, et al. Sleep loss exacerbates fatigue, depression, and pain in rheumatoid arthritis. Sleep. 2012;35(4):537–43.CrossRefGoogle Scholar
  27. 27.
    Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update and a path forward. J Pain. 2013;14(12):1539–52.CrossRefGoogle Scholar
  28. 28.
    Perrot S, et al. Antidepressant use in painful rheumatic conditions. Rheum Dis Clin N Am. 2008;34(2):433–53.CrossRefGoogle Scholar
  29. 29.
    •• Cohen E, Lee YC. A mechanism-based approach to the management of osteoarthritis pain. Curr Osteoporos Rep. 2015;13(6):399–406. The inhibition of nerve growth factor (NGF) inhibition is an emerging treatment for pain in osteoarthritis. This paper discusses results from anti-NGF clinical trials and experimental models of NGF inhibition; the risks of this therapy are also discussed.CrossRefGoogle Scholar
  30. 30.
    Welsch P, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018;2:Cd010292.Google Scholar
  31. 31.
    Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol. 2011;7(9):518–27.CrossRefGoogle Scholar
  32. 32.
    • Sofat N, et al. The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis. J Pain Res. 2017;10:2437–49. An important line of research concerns the role of various channels in pain generation. This article reviews the sodium channelopathies and the role of sodium channels in sensory neurons and human pain disorders, a potential future target in pain management.CrossRefGoogle Scholar
  33. 33.
    Miller RE, Malfait AM, Block JA. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 2017;35(Suppl 107(5)):85–7.Google Scholar
  34. 34.
    Miller RE, Block JA, Malfait AM. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? Curr Opin Rheumatol. 2017;29(1):110–8.CrossRefGoogle Scholar
  35. 35.
    Dimitroulas T, et al. Biologic drugs as analgesics for the management of osteoarthritis. Semin Arthritis Rheum. 2017;46(6):687–91.CrossRefGoogle Scholar
  36. 36.
    Hochberg MC, et al. When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheum. 2016;68(2):382–91.CrossRefGoogle Scholar
  37. 37.
    Dib-Hajj SD, Geha P, Waxman SG. Sodium channels in pain disorders: pathophysiology and prospects for treatment. Pain. 2017;158(Suppl 1):S97–s107.CrossRefGoogle Scholar
  38. 38.
    Edwards RR, et al. Pain, catastrophizing, and depression in the rheumatic diseases. Nat Rev Rheumatol. 2011;7(4):216–24.CrossRefGoogle Scholar
  39. 39.
    Adler-Neal AL, Zeidan F. Mindfulness meditation for fibromyalgia: mechanistic and clinical considerations. Curr Rheumatol Rep. 2017;19(9):59.CrossRefGoogle Scholar
  40. 40.
    Coskun Benlidayi I. Sleep impairment: an obstacle to achieve optimal quality of life in rheumatoid arthritis. Rheumatol Int. 2018.Google Scholar
  41. 41.
    Bidonde J, et al. Aerobic exercise training for adults with fibromyalgia. 2017;6:Cd012700.Google Scholar
  42. 42.
    Verhoeven F, et al. Physical activity in patients with rheumatoid arthritis. Joint Bone Spine. 2016;83(3):265–70.CrossRefGoogle Scholar
  43. 43.
    Hochberg MC, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):465–74.CrossRefGoogle Scholar
  44. 44.
    Felson DT, Hodgson R. Identifying and treating preclinical and early osteoarthritis. Rheum Dis Clin N Am. 2014;40(4):699–710.CrossRefGoogle Scholar
  45. 45.
    Macfarlane GJ, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318–28.CrossRefGoogle Scholar
  46. 46.
    Louw A, et al. The efficacy of pain neuroscience education on musculoskeletal pain: a systematic review of the literature. Physiother Theory Pract. 2016;32(5):332–55.CrossRefGoogle Scholar
  47. 47.
    Zangi HA, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis. 2015;74(6):954–62.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Rheumatology and ImmunologyDuke University Medical CenterDurhamUSA
  2. 2.Medical Research ServiceDurham VA Medical CenterDurhamUSA
  3. 3.Durham VA Medical CenterDurhamUSA

Personalised recommendations